CRBP
Corbus Pharmaceuticals Holdings, Inc.
$8.05
+2.16%
$153.0M
No data for this timeframe.
Vol
Market Cap$153.0M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (94%)
Inst. Holders45 funds
Inst. Value$35.6M
Inst. Activity7 buys / 7 sells
Insider Activity2B / 3S
Insider Net $$4.5K
Reddit Sentiment40° Cool
SEC Reports11
Press Releases1
Recent Activity
Jun 3, 2026
Insider
Saxena Nishant C bought 9,000 shares
Chief Business Officer @ $7.58 ($68.2K)
Jun 2, 2026
Insider
Saxena Nishant C bought 4,500 shares
Chief Business Officer @ $7.33 ($33.0K)
May 27, 2026
short_volume
Short Volume: CRBP — 60.0% short (0.5M / 0.9M)
Short: 529,577 | Exempt: 54,330 | TRF Vol: 881,947 | Short Ratio: 60.0% | Off-exchange volume (dark
May 26, 2026
SEC
Corbus reported updated Phase 1/2 data for CRB-701, a next-generation Nectin-4 ADC, showing a 42.9% confirmed ORR in 2L
8-K — Impact 7/10
May 21, 2026
SEC
Corbus Pharmaceuticals appointed Nishant Saxena as its first Chief Business Officer with a two-year employment agreement
8-K — Impact 4/10
May 21, 2026
Insider
Saxena Nishant C was granted 58,300 shares
Chief Business Officer
May 14, 2026
SEC
Corbus Pharmaceuticals appointed Brent Pfeiffenberger to its Board of Directors and shareholders approved an amendment t
8-K — Impact 4/10
Inst.
MARSHALL WACE, LLP — ADD
146,596 shares ($1.4M)
Price Targets
$36.50
+341.9% upside
Strong Buy
Current $8.26
Low $17.00
Median $37.00
High $54.00
10 analysts
$17.00
$54.00
Analyst Ratings
7Strong Buy
8Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 17, 2026 | Oppenheimer | MAINTAIN | Outperform → Outperform |
| May 27, 2026 | Wedbush | MAINTAIN | Outperform → Outperform |
| May 26, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| May 22, 2026 | Mizuho | MAINTAIN | Outperform → Outperform |
| May 13, 2026 | Jefferies | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-1.24 | $-1.38 — $-1.15 | 14% YoY | 10 |
| Next Q | $-1.03 | $-1.49 — $-0.63 | 46% YoY | 10 |
| Current FY | $-4.57 | $-5.70 — $-3.31 | 23% YoY | 10 |
| Next FY | $-5.07 | $-7.09 — $-2.55 | -11% YoY | 9 |
Latest Reports
BULLISH
8-K
7/10
Corbus reported updated Phase 1/2 data for CRB-701, a next-generation Nectin-4 ADC, showing a 42.9% confirmed ORR in 2L
May 26, 2026
NEUTRAL
8-K
4/10
Corbus Pharmaceuticals appointed Nishant Saxena as its first Chief Business Officer with a two-year employment agreement
May 21, 2026
MIXED
Press
6/10
Corbus Pharmaceuticals reported Q4 and full-year 2025 financial results with a wider net loss of $20.6M ($1.25/share) co
Mar 9, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $6.9M | — |
| CITADEL ADVISORS LLC | $6.8M | — |
| RENAISSANCE TECHNOLOGIES LLC | $3.3M | DOUBLED |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $3.1M | — |
| BlackRock, Inc. | $2.6M | TRIM |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 3, 2026 | Saxena Nishant | BUY | $68.2K |
| Jun 2, 2026 | Saxena Nishant | BUY | $33.0K |
| May 21, 2026 | Saxena Nishant | A | $0.00 |
| May 21, 2026 | Saxena Nishant | A | $0.00 |
| May 19, 2026 | Pfeiffenberger Brent | A | $0.00 |
Reddit Sentiment
40°
Cool
Bearish
Neutral
Bullish
45 institutional holders with $35.6M total value (3,817,352 shares) as of 2026-Q1. Top holders: VANGUARD, CITADEL, RENAISSANCE.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 734,106 | $6.9M | 19.4% | — |
| 2 | CITADEL ADVISORS LLC | 727,060 | $6.8M | 19.2% | — |
| 3 | RENAISSANCE TECHNOLOGIES LLC | 346,998 | $3.3M | 9.2% | DOUBLED +230.5% |
| 4 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 333,415 | $3.1M | 8.8% | — |
| 5 | BlackRock, Inc. | 271,636 | $2.6M | 7.2% | TRIM -35.6% |
| 6 | MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 160,462 | $1.5M | 4.2% | DOUBLED +112.1% |
| 7 | MARSHALL WACE, LLP | 146,596 | $1.4M | 3.9% | ADD +89.0% |
| 8 | DIMENSIONAL FUND ADVISORS LP | 136,602 | $1.3M | 3.6% | ADD +76.6% |
| 9 | VANGUARD FIDUCIARY TRUST CO | 96,241 | $903.7K | 2.5% | — |
| 10 | GOLDMAN SACHS GROUP INC | 93,111 | $874.3K | 2.5% | — |
| 11 | Assenagon Asset Management S.A. | 85,246 | $800.5K | 2.3% | TRIM -54.6% |
| 12 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 71,900 | $675.1K | 1.9% | — |
| 13 | STATE STREET CORP | 68,872 | $646.7K | 1.8% | ADD +25.0% |
| 14 | CITADEL ADVISORS LLC | 67,900 | $637.6K | 1.8% | — |
| 15 | BALYASNY ASSET MANAGEMENT L.P. | 65,201 | $612.2K | 1.7% | TRIM -51.1% |
| 16 | Point72 Asset Management, L.P. | 51,296 | $481.7K | 1.4% | TRIM -31.7% |
| 17 | MORGAN STANLEY | 32,854 | $308.5K | 0.9% | ADD +46.8% |
| 18 | Brevan Howard Capital Management LP | 32,679 | $306.9K | 0.9% | ADD +73.9% |
| 19 | ROYAL BANK OF CANADA | 29,901 | $281.0K | 0.8% | ADD +42.3% |
| 20 | Hudson Bay Capital Management LP | 29,578 | $277.7K | 0.8% | ADD +73.1% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MARSHALL WACE, LLP | ADD | 77,546 | 146,596 | +89.0% | $1.4M | 2026-Q1 |
| DIMENSIONAL FUND ADVISORS LP | ADD | 77,354 | 136,602 | +76.6% | $1.3M | 2026-Q1 |
| Assenagon Asset Management S.A. | TRIM | 187,956 | 85,246 | -54.6% | $800.5K | 2026-Q1 |
| STATE STREET CORP | ADD | 55,092 | 68,872 | +25.0% | $646.7K | 2026-Q1 |
| BALYASNY ASSET MANAGEMENT L.P. | TRIM | 133,311 | 65,201 | -51.1% | $612.2K | 2026-Q1 |
| Point72 Asset Management, L.P. | TRIM | 75,134 | 51,296 | -31.7% | $481.7K | 2026-Q1 |
| MORGAN STANLEY | ADD | 22,381 | 32,854 | +46.8% | $308.5K | 2026-Q1 |
| Brevan Howard Capital Management LP | ADD | 18,795 | 32,679 | +73.9% | $306.9K | 2026-Q1 |
| Hudson Bay Capital Management LP | ADD | 17,089 | 29,578 | +73.1% | $277.7K | 2026-Q1 |
| OMERS ADMINISTRATION Corp | TRIM | 30,000 | 15,200 | -49.3% | $142.7K | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 26 | 13,960 | +53592.3% | $131.1K | 2026-Q1 |
| Mariner, LLC | TRIM | 17,086 | 12,806 | -25.0% | $120.2K | 2026-Q1 |
| FMR LLC | TRIM | 1,129 | 688 | -39.1% | $6.5K | 2026-Q1 |
| CWM, LLC | TRIM | 149 | 69 | -53.7% | $648.00 | 2026-Q1 |
| VANGUARD GROUP INC | ADD | 612,030 | 859,407 | +40.4% | $7.0M | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 107,200 | 354,300 | +230.5% | $2.9M | 2025-Q4 |
| Assenagon Asset Management S.A. | DOUBLED | 85,347 | 187,956 | +120.2% | $1.5M | 2025-Q4 |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | DOUBLED | 85,826 | 182,062 | +112.1% | $1.5M | 2025-Q4 |
| AMERIPRISE FINANCIAL INC | ADD | 69,625 | 135,730 | +94.9% | $1.1M | 2025-Q4 |
| BALYASNY ASSET MANAGEMENT L.P. | DOUBLED | 23,418 | 133,311 | +469.3% | $1.1M | 2025-Q4 |
| D. E. Shaw & Co., Inc. | DOUBLED | 10,627 | 28,794 | +171.0% | $234.4K | 2025-Q4 |
| Trexquant Investment LP | DOUBLED | 12,165 | 27,275 | +124.2% | $222.0K | 2025-Q4 |
| MORGAN STANLEY | NEAR_EXIT | 154,842 | 22,381 | -85.5% | $182.2K | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 26,457 | 12,480 | -52.8% | $101.6K | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | DOUBLED | 1 | 44 | +4300.0% | $358.00 | 2025-Q4 |
9 unique insiders with 19 transactions. Net insider value: $4.5K ($101.2K bought, $96.7K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 3, 2026 | Saxena Nishant C | Chief Business Officer | BUY | 9,000 | $7.58 | $68.2K |
| Jun 2, 2026 | Saxena Nishant C | Chief Business Officer | BUY | 4,500 | $7.33 | $33.0K |
| May 21, 2026 | Saxena Nishant C | Chief Business Officer | AWARD | 58,300 | — | — |
| May 21, 2026 | Saxena Nishant C | Chief Business Officer | AWARD | 192,300 | — | — |
| May 19, 2026 | Pfeiffenberger Brent | Director | AWARD | 24,700 | — | — |
| May 19, 2026 | Pfeiffenberger Brent | Director | AWARD | 7,500 | — | — |
| May 19, 2026 | Jacques Rachelle Suzanne | Director | AWARD | 3,800 | — | — |
| May 19, 2026 | Altmeyer Anne | Director | AWARD | 3,800 | — | — |
| May 19, 2026 | Altmeyer Anne | Director | AWARD | 12,300 | — | — |
| May 19, 2026 | Kung Winston | Director | AWARD | 3,800 | — | — |
| May 19, 2026 | Jenkins John Kenneth | Director | AWARD | 12,300 | — | — |
| May 19, 2026 | Ben Yong | Director | AWARD | 3,800 | — | — |
| May 19, 2026 | Ben Yong | Director | AWARD | 12,300 | — | — |
| May 19, 2026 | Jenkins John Kenneth | Director | AWARD | 3,800 | — | — |
| May 19, 2026 | Jacques Rachelle Suzanne | Director | AWARD | 12,300 | — | — |
| May 19, 2026 | Kung Winston | Director | AWARD | 12,300 | — | — |
| Mar 2, 2026 | Smethurst Dominic | Chief Medical Officer | SELL | 6,097 | $8.30 | $50.6K |
| Feb 3, 2026 | Smethurst Dominic | Chief Medical Officer | SELL | 3,285 | $8.09 | $26.6K |
| Feb 3, 2026 | Hodgson Ian | Chief Operating Officer | SELL | 2,415 | $8.09 | $19.5K |
11 SEC filing reports analyzed. Sentiment: 2 bullish, 1 bearish, 2 mixed, 6 neutral. Avg impact: 5.1/10.
BULLISH
8-K
7/10
Corbus reported updated Phase 1/2 data for CRB-701, a next-generation Nectin-4 ADC, showing a 42.9%
May 26, 2026
NEUTRAL
8-K
4/10
Corbus Pharmaceuticals appointed Nishant Saxena as its first Chief Business Officer with a two-year
May 21, 2026
NEUTRAL
8-K
4/10
Corbus Pharmaceuticals appointed Brent Pfeiffenberger to its Board of Directors and shareholders app
May 14, 2026
MIXED
8-K
5/10
Corbus Pharmaceuticals reported Q1 2026 net loss of $23.0M ($1.23/share), slightly beating the $1.26
May 12, 2026
NEUTRAL
PRESS-RELEASE
4/10
Corbus reported Q1 2026 net loss of $23.0M ($1.23/share), slightly missing consensus EPS of -$1.22.
May 12, 2026
NEUTRAL
8-K
4/10
Corbus Pharmaceuticals renewed employment agreements with CEO Yuval Cohen and CFO Sean Moran, effect
Apr 16, 2026
NEUTRAL
8-K
4/10
Corbus Pharmaceuticals announced the last patient has completed their first visit in the CANYON-1 Ph
Apr 14, 2026
MIXED
8-K
6/10
Corbus Pharmaceuticals announced broad alignment with the FDA on the registration path for its oncol
Apr 7, 2026
NEUTRAL
EFFECT
4/10
Corbus Pharmaceuticals Holdings, Inc. (CRBP) has announced the effectiveness of a shelf registration
Mar 23, 2026
BEARISH
S-3
7/10
Corbus Pharmaceuticals filed an S-3 shelf registration, signaling potential future share issuance. T
Mar 11, 2026
BULLISH
8-K
7/10
Corbus Pharmaceuticals updated its corporate presentation with positive clinical data from its pipel
Feb 25, 2026
Current analyst consensus: Strong Buy (94% buy). Based on 16 analysts: 7 strong buy, 8 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$36.50 mean target
+341.9% upside
Strong Buy (3.00)
$17.00 Low
$54.00 High
| Metric | Value |
|---|---|
| Current Price | $8.26 |
| Target Low | $17.00 |
| Target Mean | $36.50 |
| Target Median | $37.00 |
| Target High | $54.00 |
| # Analysts | 10 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-1.24 | $-1.38 | $-1.15 | 14.1% | — | 0↑ 3↓ | $0.0B | 0.0% | 10 |
| Next Q 2026-09-30 |
$-1.03 | $-1.49 | $-0.63 | 45.6% | — | 3↑ 4↓ | $0.0B | 0.0% | 10 |
| Current FY 2026-12-31 |
$-4.57 | $-5.70 | $-3.31 | 22.6% | -0.2% | 4↑ 4↓ | $0.0B | 0.0% | 10 |
| Next FY 2027-12-31 |
$-5.07 | $-7.09 | $-2.55 | -11.1% | — | 2↑ 6↓ | $0.0B | 116.0% | 9 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-1.237 | |
| 7d ago | $-1.237 | -0.000 |
| 30d ago | $0.000 | -1.237 |
| 60d ago | $-1.236 | -0.001 |
| 90d ago | $-1.415 | +0.178 |
6 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 17, 2026 | Oppenheimer | MAINTAIN | Outperform | Outperform |
| May 27, 2026 | Wedbush | MAINTAIN | Outperform | Outperform |
| May 26, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 22, 2026 | Mizuho | MAINTAIN | Outperform | Outperform |
| May 13, 2026 | Jefferies | MAINTAIN | Buy | Buy |
| May 13, 2026 | Oppenheimer | MAINTAIN | Outperform | Outperform |
| May 13, 2026 | Guggenheim | REITERATE | Buy | Buy |
| Apr 29, 2026 | Guggenheim | INITIATE | — | Buy |
| Mar 10, 2026 | Oppenheimer | MAINTAIN | Outperform | Outperform |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 7 | 8 | 1 | 0 | 0 | 94% | |
| May 1, 2026 | 7 | 8 | 1 | 0 | 0 | 94% | |
| Apr 1, 2026 | 6 | 9 | 1 | 0 | 0 | 94% | |
| Mar 1, 2026 | 6 | 9 | 1 | 0 | 0 | 94% | |
| Feb 1, 2026 | 6 | 9 | 1 | 0 | 0 | 94% | |
| Jan 1, 2026 | 6 | 9 | 1 | 0 | 0 | 94% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
40°
Cool
Bearish
Neutral
Bullish
1 mentions
0 bullish
1 bearish
1 time period
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Feb 26, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
Recent Reddit Threads
CRBP -- going to run up
▲ 1
💬 2
⚡ 0.0
May 27, 2026
short_volume
Short Volume: CRBP — 60.0% short (0.5M / 0.9M)
Short: 529,577 | Exempt: 54,330 | TRF Vol: 881,947 | Short Ratio: 60.0% | Off-exchange volume (dark pool + OTC)
May 26, 2026
fda
Corbus Pharmaceuticals Reports Updated CRB-701 Phase 1/2 Clinical Data Demonstrating Robust Activity in 2L Oropharyngeal and Cervical Cancers
<p align="justify">NORWOOD, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”)
May 13, 2026
other
Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences
<p align="justify">NORWOOD, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP), a clinical-stage company f
May 12, 2026
earnings
Corbus Pharmaceuticals Reports Q1 2026 Financial Results and Provides a Corporate Update
<p align="justify">NORWOOD, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”)
May 6, 2026
Clinical Trial
JBT-101 in Systemic Lupus Erythematosus (SLE)
Phase Phase 2 — COMPLETED
May 4, 2026
earnings_calendar
CRBP Q1 2026 Earnings Scheduled — 2026-05-04
Mar 9, 2026
earnings
Corbus Pharmaceuticals Reports Q4 and 2025 Financial Results and Provides a Corporate Update
<p align="justify">NORWOOD, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company
Mar 9, 2026
earnings_calendar
CRBP Q4 2025 Earnings After Market Close — 2026-03-09